“…As the authors noted , CHEK2 PGVs in patients with NSCLC are rare (<1%), and, therefore, universal germline testing of patients with NSCLC to identify CHEK2 PGV carriers is problematic. 1 However, germline testing is recommended for all patients with tumors exhibiting probable incidental CHEK2 PGVs; the current routine next-generation sequencing of NSCLCs will—when CHEK2 is interrogated—identify probable incidental CHEK2 PGVs, and, therefore, a group that particularly should consider undergoing germline testing. 2…”